US12606631B2 - ETAR Antibodies, Patent Grant
Summary
USPTO granted Patent US12606631B2 to REMD Biotherapeutics Inc for isolated antibodies that specifically bind endothelin A receptor (ETAR). The antibodies have high affinity for ETAR, block ET-1 binding to ETAR, exhibit reduced immunogenicity, and have longer serum half-life compared to small molecule ETAR antagonists. Seven claims were allowed.
What changed
USPTO issued Patent US12606631B2 to REMD Biotherapeutics Inc covering isolated antibodies and antigen-binding fragments that specifically bind endothelin A receptor (ETAR). The patent claims ETAR antibodies with high affinity, ability to block ET-1 binding, reduced immunogenicity, and longer serum half-life relative to small molecule antagonists.
Parties developing ETAR-targeted therapeutics should review this patent landscape to assess freedom-to-operate considerations. The patent's allowed claims covering ETAR antibody composition and methods of treating ETAR-associated disorders may be relevant to competitors in the biopharmaceutical space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibodies which bind human endothelin receptor a (ETAR)
Grant US12606631B2 Kind: B2 Apr 21, 2026
Assignee
REMD Biotherapeutics Inc
Inventors
Hai Yan, John Zhang
Abstract
This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind endothelin A receptor (ETAR). These ETAR antibodies, or antigen-binding fragments thereof, have a high affinity for ETAR, function to effectively block ET-1 binding to ETAR, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat ETAR-associated disorders. Importantly, compared to small molecule ETAR antagonists, the antibodies of the present invention have advantages of longer serum half-life, higher target specificity, thereby limiting the risk of off-target toxicity and improving therapeutic window.
CPC Classifications
C07K 16/2869 C07K 2317/24 C07K 2317/55 C07K 2317/565 C07K 2317/92 C07K 2317/76
Filing Date
2021-05-19
Application No.
17926295
Claims
7
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.